

ORIGINAL ARTICLE

α B-crystallin (HspB5) in familial amyloidotic polyneuropathy

Joana Magalhães^{*,†}, Sofia Duque Santos^{*} and Maria João Saraiva^{*,†}

^{*}IBMC, Instituto de Biologia Molecular e Celular, Porto, Portugal and [†]ICBAS, Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Porto, Portugal

INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY

Summary

The small heat shock protein α B-crystallin (HspB5) is known to be overexpressed in several neurodegenerative disorders. In familial amyloidotic polyneuropathy (FAP), a neurodegenerative disorder characterized by extracellular deposition of mutated transthyretin (TTR), activation of heat shock factor 1 -HSF1- by extracellular TTR deposition has been shown as well as induction of the expression of heat shock proteins, HSP27 and HSP70. Here we investigate the expression of α B-crystallin in FAP. We first detected α B-crystallin in aggregates extracted from tissues of both FAP patients and transgenic mice for the human V30M mutant TTR; however, subsequent studies by confocal fluorescence microscopy did not confirm the association of α B-crystallin with TTR aggregates; thus the presence of α B-crystallin in aggregate extracts might derive from the extraction procedure. Increased levels of α B-crystallin were observed by immunohistochemistry in human FAP skin, as compared to normal skin. Furthermore, skin, stomach and dorsal root ganglia from V30M transgenic mice showed increased expression of α B-crystallin as compared to controls without deposition. A human neuroblastoma cell line incubated with TTR aggregates displayed increased expression of α B-crystallin. Overall, these results show that extracellular TTR deposits induce an intracellular response of α B-crystallin. This small heat shock protein (HSP), which is important for anti-apoptotic and chaperone properties, may have a protective role in FAP.

Keywords

amyloid, crystallin, heat shock response, transthyretin

doi: 10.1111/j.1365-2613.2010.00735.x

Received for publication:
17 August 2009
Accepted for publication:
20 June 2010

Correspondence:

Maria João Saraiva
Molecular Neurobiology
IBMC R. Campo Alegre 823
4150, Porto
Portugal
Tel.: +351 226074900
Fax: +351 226099157
E-mail: mjsaraiv@ibmc.up.pt

Heat shock proteins (Hsps) expression is increased in response to heat shock or other stresses including protein misfolding and aggregation. Activation of the heat shock factor-1 (HSF-1) has a major role in this process; small Hsps of low molecular masses (<43 kDa) are a family of chaperones that have a conserved α -crystallin domain in the c-terminal domain; α B-crystallin (HspB5), is a small Hsp (Klemenz *et al.* 1991) that was primarily found in the eye lens and is constitutively expressed in many tissues. Anti-apoptotic properties of α B-crystallin have been described; thus, it binds to pro-apoptotic Bax, Bcl-xs and p53 and prevents their translocation to mitochondria (Mao *et al.* 2004; Liu *et al.* 2007); moreover, α B-crystallin inhibits the activation of pro-caspase-3 (Kamradt *et al.* 2005); phosphorylation at three serine residues (Ser¹⁹, Ser⁴⁵ and Ser⁵⁹) in α B-crystallin regulates its chaperone activity (Ecroyd *et al.* 2007). α B-crystallin can form oligomers with other Hsps, namely with HSP27 and presents ATP-independent

chaperone activity. Oligomer size and chaperone activity is modified by phosphorylation (Jakob *et al.* 1993); 'in vitro', α B-crystallin inhibits fibril formation of amyloid β -peptide and β ₂-microglobulin (Raman *et al.* 2005). Increased expression of α B-crystallin has been found in Alzheimer disease (AD) (Björkdahl *et al.* 2008); however, there is no co-localization of α B-crystallin and amyloid β -peptide in senile plaques of AD brains (Wilhelmus *et al.* 2006). The presence of α B-crystallin in alpha-synuclein inclusions was described as well, but in this case, α B-crystallin co-localized with alpha-synuclein in Lewy bodies (Outeiro *et al.* 2006). In mouse models of Parkinson disease the levels of α B-crystallin were found to be higher than controls; in Huntington's disease, it was found that mice lacking α B-crystallin had accelerated onset and severity in aggregation (Ecroyd & Carver 2009). All these data shows association of α B-crystallin with neurodegenerative disorders and reveal a probable protection function for α B-crystallin.

Familial amyloid polyneuropathy (FAP) is an autosomal dominant neurodegenerative disorder characterized by the systemic extracellular deposition of mutated transthyretin (TTR) that affects particularly the peripheral nervous system (PNS) (Andrade 1952; Costa *et al.* 1978). The most common mutation associated with FAP is TTRV30M, (Saraiva *et al.* 1984). TTR is a tetrameric serum protein of four identical subunits of 14 kDa. Amyloidogenic mutations on TTR favour destabilization and dissociation of the tetrameric structure, leading to misfolded intermediates with high tendency for extracellular aggregation (Cardoso *et al.* 2002). In asymptomatic carriers (FAP 0) deposition of TTR in an aggregated non-fibrillar form occurs. In later stages of the disease, non-fibrillar and fibrillar deposits co-exist (Sousa *et al.* 2001a).

Recently, the heat shock response was investigated in FAP through expression analyses of heat shock factor 1 (HSF1), HSP27 and HSP70. It was demonstrated that in FAP, extracellular TTR deposition induces intracellular activation of HSF1 and increases expression of HSP27 and HSP70 (Santos *et al.* 2008). Here, we investigate the presence of α B-crystallin in TTR tissue aggregate extracts from human FAP and transgenic mice for human V30M TTR. We also analyzed the expression of α B-crystallin in FAP biopsies, in tissues from transgenic mice and in a human neuroblastoma cell line incubated with TTR aggregates.

Materials and methods

Human tissue samples

Autopsy kidney tissues from V30M FAP patients and normal controls were available at the Hospital Geral de Santo António, Porto, Portugal. Skin from FAP patients and normal controls was obtained as part of the clinical diagnosis and evaluation of FAP, prior to the current use of less invasive molecular diagnostic methods. The use of these materials was approved by the ethical committee of Hospital Geral de Santo António, Porto, Portugal. Human tissue processing and characterization was performed as described previously (Santos *et al.* 2008) and included both asymptomatic carriers (FAP 0) and patients (FAP). Control biopsies were from FAP relatives who were later characterized as non-V30M carriers.

Mouse tissue samples

Different strains of transgenic mice for TTR V30M, all in the Sv129 background were used in this study: (i) TTRV30M without endogenous TTR, labelled hTTR (Kohno *et al.* 1997); (ii) this strain crossed to homozygous or heterozygous heat shock transcription factor 1 (HSF1) null mice, labelled either hTTR HSF1 or hTTR HSF1-het respectively (Santos *et al.* 2010).

Animals age ranged from 6 to 18 months. The animals were housed in pathogen-free conditions in a controlled-temperature room, maintained under a 12 h light/dark period. Water and food were freely available. Animal experiments

were carried out in accordance with the European Communities Council Directive. Tissues were processed for immunohistochemistry, as previously described (Santos *et al.* 2008) or frozen for further analysis. Mice tissues were analyzed for TTR deposition by immunohistochemistry as previously described (Sousa *et al.* 2002) and classified by the presence and types of deposits: TTR^{-/-} no TTR deposits; TTR^{+/-} only non-fibrillar TTR deposits (congo red negative); TTR^{+/+} non-fibrillar and fibrillar TTR deposition (congo red positive)

Aggregate extraction

For aggregate extraction, we used the Kaplan method (Kaplan *et al.* 1994); 100 mg of autopsy samples of human FAP and control kidney and stomach from transgenic mice ($n = 3$) were homogenized in ice cold phosphate buffered solution (PBS; 1 ml), centrifuged at 19,000 g for 10 min and 1 ml of PBS added to the pellet. This procedure was repeated twice; the pellet was then rinsed with distilled water and resuspended in 20% acetonitrile/0.1% trifluoroacetic acid (TFA), incubated for 1 h at room temperature with mixing and centrifuged at 19,000 g for 10 min; the supernatant was saved and the extraction repeated twice. The supernatants were pooled and lyophilized. The samples were resuspended in Laemli SDS sample buffer, applied in a 15% SDS-PAGE gel and analyzed by western blotting for α B-crystallin (1:1000; abcam, Cambridge, UK); parallel silver stained bands were subjected to mass spectrometry analysis.

Mass spectrometry

Human kidney aggregate extracts were run in SDS-PAGE and silver stained. After silver stain, a band with molecular weight above the normal migration of the TTR monomer and with molecular weight corresponding to α B-crystallin, was excised from the gel and digested with endoproteinase Lys-C. MALDI mass spectroscopic analysis was performed on a PerSeptive Voyager mass spectrometer in the linear mode (Henzel *et al.* 1993).

Western blot

Transgenic mice stomach samples ($n = 4$) were homogenized in lysis buffer: 20 mM MOPS, 2 mM EGTA, 5 mM EDTA, 30 mM sodium fluoride, 40 mM β -glycerophosphate, 20 mM sodium pyrophosphate, 1 mM sodium orthovanadate, 1 mM phenylmethylsulphonyl fluoride, 0.5% Triton X-100 and 1x protease inhibitors mixture (Amersham Bioscience, Little Chalfont, UK). Total protein concentration was determined using the Bio-Rad assay kit (Bio-Rad, Hercules, CA, USA). 40 μ g of total protein was applied to 12% SDS-PAGE and transferred onto a nitrocellulose Hybond-C membrane (Amersham Bioscience) using a semidry system. The primary antibodies used were rabbit anti- α B-crystallin (1:1000; abcam) and rabbit anti- β -actin (1:250; Sigma-Aldrich, St. Louis, MO, USA) for normalization. To develop the blots, enhanced chemilumi-

nescence (ECL, Amersham Bioscience) was performed. Quantitative analysis of the western blots was performed with ImageQuant software.

Immunohistochemistry

Tissue paraffin slides of human and transgenic mice skin were deparaffinated and hydrated. Epitope exposure with citrate buffer was performed; endogenous peroxidase activity was blocked with 3% hydrogen peroxide in methanol for 30 min. The slides were incubated in blocking buffer (4% foetal bovine serum and 1% bovine serum albumin in PBS) for 1 h at 37 °C in a humidified chamber. Incubation with primary rabbit α B-crystallin antibody (1:1000; Calbiochem, San Diego, CA, USA) in blocking buffer was performed overnight at 4 °C. Antibody binding was detected by a biotin-extravidin-peroxidase kit (Sigma-Aldrich) using as substrate 3-amino-9-ethyl carbazole, AEC, (Sigma). Semi-quantitative analysis of the immunostaining was performed in four different areas of the tissue with Image Pro-Plus software; obtained results represent the percentage of occupied area by the substrate reaction colour normalized with the total area occupied by the tissue. The observer was blind to treatment/control samples statistical significance was determined using Student's *t*-test, a minimal *P* value of <0.05 was required for significance. Experiments were carried out in four tissue samples from transgenic mice and in five samples from human skin tissues.

For double-immunofluorescence, paraffin slides of human skin were treated as previously described for immunohistochemistry. Primary antibodies were: mouse anti-human TTR (mab15 1 μ g/ml) kindly provided by Dr Erik Lundgren from Umea University (Pokrzywa *et al.* 2007) and rabbit α B-crystallin (1:200; abcam), incubated overnight at 4 °C in blocking buffer. The secondary antibodies used were Alexa Fluor 568 anti-mouse and Alexa Fluor 488 anti-rabbit (1:1000; Molecular Probes, Eugene, OR, USA) which were incubated for 1 h at room temperature protected from light. Slides were mounted with Vectashield (Vector, Burlingame, CA, USA) and visualized by confocal microscopy (Leica TCS SP2 AOBS).

Protein

Recombinant wild-type TTR was produced in an *Escherichia coli* BL21 expression system and purified as previously described (Furuya *et al.* 1991). TTR was dialyzed against water, diluted to 0.250 mg ml⁻¹ and then stirred at room temperature for 7 days. Oligomeric preparations were tested by thioflavin T spectrofluorometric assay and were stable in serum free media as previously described (Teixeira *et al.* 2006).

Cell culture assays

Cells were maintained at 37 °C in a 5% CO₂ humidified atmosphere. A SH-SY5Y human neuroblastoma cell line

(European Collection of Cell Cultures) was cultured in MEM:F12 (Gibco; Invitrogen, Grand Island, NY, USA) supplemented with 15% foetal bovine serum (Gibco, Invitrogen), 2 mmol⁻¹ of glutamine (Gibco, Invitrogen), 100 Uml⁻¹ penicillin/streptavidin (Gibco, Invitrogen) and 1 mmol⁻¹ of non-essential amino acids (Sigma-Aldrich). One hour before incubation, cell medium was changed to serum free medium. Cells were incubated for 8 h with oligomeric and soluble TTR (0.110 mg ml⁻¹) and collected in Trizol (Invitrogen) for RNA extraction which was performed according to the manufacturer's instructions. Synthesis of cDNA was performed using the SuperScript double-stranded cDNA Kit (Invitrogen). Reverse-transcriptase polymerase chain reaction was performed for human α B-crystallin with primers: forward 5'-AGCTGGTTTGACACTGGACT-3' (annealing from nucleotide 200–219, exon 1) and reverse 5'-GCAATTCAGAAAGGGCATC-3' (annealing from nucleotide 572–553, exon 3); for human β -actin primers were: forward 5'-ATGGATGATGATATCGCCGCG-3' (annealing from nucleotide 85–105, exon 2) and reverse 5'-TCTCCATGTCGTCCCAGTTG-3' (annealing from nucleotide 334–315, exon 3). The amplification products were quantified with the ImageQuant software. Three independent experiments with duplicates were performed.

Results

Human α B-crystallin in aggregate preparations

We analyzed TTR aggregates extracted from human kidney samples and from stomach of transgenic mice. Human kidney aggregate extracts from FAP and control human kidney were separated by SDS-PAGE followed by silver staining; a band at approximately 20 kDa migrating above the TTR monomer (Figure 1a) was subjected to mass spectrometry and was identified as human α B-crystallin. To confirm the




Figure 1 (a) SDS-PAGE silver stain of FAP human kidney aggregate extracts and TTR standard; the α B-crystallin band is pointed out by a rectangle. (b) α B-crystallin western blot of i) human normal and FAP kidney; ii) transgenic mice stomach aggregate extracts (*n* = 3 each) with and without TTR deposition (TTR+ and TTR- respectively)




Figure 2 Immunofluorescence in human FAP skin for TTR (red) and α B-crystallin (green) showing no co-localization of the two proteins, with α B-crystallin staining intracellularly and TTR extracellularly (bar = 50 μ m).

presence of α B-crystallin in the preparation, the same extract was then analyzed by western blot for α B-crystallin; as seen in Figure 1b i), α B-crystallin was detected in the FAP preparation and was absent in normal kidney extracts. TTR preparations from the stomach of transgenic mice with or without TTR deposition (TTR+ and TTR- respectively) were also analysed by western blot for the presence of α B-crystallin; this protein was detected in the preparations containing TTR aggregates, as opposed to the preparation derived from tissues without TTR deposits (Figure 1b ii), indicating that α B-crystallin might be a component of TTR deposits.




Figure 3 TTR deposition induces α B-crystallin expression. (a) immunohistochemistry of human skin, showing increased expression in FAP 0 ($n = 5$) and FAP patients ($n = 3$) when compared to controls ($n = 5$) (bar = 200 μ m); (b) immunohistochemistry of transgenic mice skin: increased expression of α B-crystallin in TTR+/- ($n = 4$) and TTR+/+ ($n = 4$) transgenic mice when compared to mice without TTR deposits, TTR-/- ($n = 5$) (bar = 50 μ m); (c) western blot of transgenic mice skin for α B-crystallin: increased expression of α B-crystallin in animals with TTR deposits (TTR+/-, $n = 4$) when compared with animals without TTR deposits (TTR-/-, $n = 4$); (d) immunohistochemistry of hTTR HSF1-het transgenic mice DRG, showing increased expression of α B-crystallin in mice with TTR deposits (TTR+/-, $n = 4$) when compared to mice without TTR deposition (TTR-/-, $n = 4$) (bar = 100 μ m); (e) Western blot analysis of α B-crystallin expression in DRG of hTTR HSF1-het showing increased expression of α B-crystallin in mice with TTR deposits (TTR+/-, $n = 7$) when compared to mice without TTR deposition (TTR-/-, $n = 7$). Quantification of images and blots are shown on the charts on the right (* $P < 0.01$, ** $P < 0.005$).




Figure 4 α B-crystallin expression in human neuroblastoma cells (SH-SY5Y) (a) α B-crystallin reverse transcriptase polymerase chain reaction of SH-SY5Y cells incubated with TTR oligomers for 8 h. Up-regulation of α B-crystallin mRNA is observed in cells incubated with TTR oligomers (oTTR) when compared to controls. (b) Western Blot analysis of α B-crystallin in SH-SY5Y cells incubated with TTR oligomers for 8 h. i) Western blot of recombinant α B-crystallin (22 kDa). ii) Increase expression of α B-crystallin in cells incubated with TTR oligomers when compared to controls. This result was confirmed by three independent experiments. (LMW represents low molecular weight standard); an unspecific band below 20 kDa is observed in all samples.

α B-crystallin localization in human FAP skin

Because α B-crystallin was detected in human TTR aggregate preparations we examined by double immunofluorescence staining the localization of α B-crystallin and TTR deposits in human skin from FAP patients; no co-localization was found; thus, α B-crystallin stained intracellularly whilst TTR deposits were found extracellularly (Figure 2).

Increased α B-crystallin expression in human FAP tissues and in transgenic mouse tissues with TTR deposition

We investigated the expression of α B-crystallin in human skin biopsies of FAP patients with proven TTR deposits, of asymptomatic carriers of TTR V30M (FAPO) and of control biopsies by semi-quantitative immunohistochemistry. Both FAP 0 and FAP samples showed a significant increase of α B-crystallin expression when compared to normal individuals (Figure 3a).

Next, we investigated the expression of α B-crystallin in transgenic mice. Mice transgenic for TTR V30M in a wild type background (hTTR) present systemic TTR deposition in several tissues, including skin, gastrointestinal track but not in the peripheral nervous system, as humans do. Skin and stomach tissues with and without TTR deposition were used to investigate α B-crystallin expression by semi-quantitative immunohistochemistry. Increased expression of α B-crystallin was detected in both skin (Figure 3b) and stomach (data not shown) of mice with deposited TTR, indepen-

dently of the type of deposit, i.e., it occurs in tissues with fibrillar or non-fibrillar deposits. To confirm this result we performed western blot analysis of skin homogenates from TTR V30M transgenic mice with and without TTR deposition; the level of α B-crystallin was significantly increased in transgenic animals with TTR deposition (Figure 3c).

Next, we investigated α B-crystallin expression in dorsal root ganglia (DRG) of transgenic mice for TTR V30M in a heterozygotic HSF1 background (hTTR HSF1-het); this strain of mice present TTR deposition in the peripheral nervous system. Therefore, immunohistochemistry and western blot was performed in mice DRG with and without deposition of TTR. The results show increased expression of α B-crystallin in DRG with TTR deposition (Figures 3d and e). Transgenic mice for TTR V30M without HSF1 (hTTR HSF1) do not show any α B-crystallin response to TTR deposition, as expected, since α B-crystallin is under the control of HSF1 (data not shown).

Increased α B-crystallin expression is induced by small TTR oligomers

The human neuroblastoma SH-SY5Y cell line was used to analyze the effect of small TTR oligomers on α B-crystallin expression. We found that oligomeric TTR (oTTR) increases α B-crystallin mRNA (Figure 4a) and protein expression (Figure 4b), as compared to non-treated cells (NT), or cells incubated with soluble TTR (sTTR).

Discussion

Different reports point out neuroprotection properties of HSPs in neurodegenerative disorders (Sittler *et al.* 2001; Magrané *et al.* 2004; Shen *et al.* 2005). In AD, HSPs are known to be associated with senile plaques (Wilhelmus *et al.* 2006), which might impact in delaying AD pathology. Concerning the small Hsp α B-crystallin a study showed increased expression in AD patients brains, mainly in astrocytes, microglia, and oligodendrocytes restricted to areas with senile plaques and neurofibrillary tangles (Renkawek *et al.* 1994); other study, showed that three α B-crystallin-related small Hsps co-localized with intracellular β amyloid peptide indicating that chaperone activity might modulate intracellular β amyloid peptide metabolism and toxicity (Fonte *et al.* 2002). These reports, point out to an important role of α B-crystallin in neurodegenerative disorders.

Here, we first detected the presence of α B-crystallin in human and transgenic mice TTR aggregate extracts suggestive of a direct interaction between extracellular deposited TTR and this chaperone; an *in vitro* study showed that specific interactive sequences of human α B-crystallin modulate the fibrillation of TTR (Ghosh *et al.* 2008), hypothesizing a possible important role for this protein in FAP; however, in view of our analyses in human FAP skin by confocal fluorescence microscopy that did not reveal any co-localization between TTR deposits and α B-crystallin, a direct *in vivo* TTR (or TTR aggregates)- α B-crystallin interaction is highly unlikely to

occur. This discrepancy in the results of aggregate analysis and confocal microscopy might be due to the extraction procedure; thus, during this procedure, cells burst and release intracellular proteins, such as chaperones that then contact with extracellular aggregates.

We also analyzed the expression of α B-crystallin in tissues that do not synthesize TTR. Increased levels of α B-crystallin were detected both in human tissues as well as in transgenic mice when extracellular TTR aggregates were evident; this increased expression was already detected in initial stages of deposition, when non-fibrillar TTR material (mice classified TTR+/- and asymptomatic FAP carriers) is present and mature fibrillar material is still absent. Thus, the α B-crystallin response is an early event in FAP. Intracellular α B-crystallin increase in the presence of TTR aggregates was also evident in our cellular studies in a neuroblastoma cellular model.

Recently, it was observed that extracellular TTR deposition is capable of exerting an intracellular stress response by increasing the expression of hsp 27 and hsp70 (Santos et al. 2008, 2010). Like hsp27 and hsp70, α B-crystallin is probably being over-expressed as one of the molecular chaperones involved in this general stress response to extracellular TTR deposition. A recent study showed that UPS (ubiquitin-proteasome system) is impaired in FAP and that unfolded/aggregated proteins accumulate inside cells (Santos et al. 2007); it is possible that α B-crystallin, as a molecular chaperone, is being over-expressed in order to deal with the increase of intracellular aggregates. Like other HSPs, α B-crystallin is known to be anti-apoptotic; it can interact with proteins in the apoptotic caspase dependent pathway modulating cell death (Mao et al. 2004; Kamradt et al. 2005). This fact is relevant in FAP since cellular death occurs, at least in part, through caspase-3 activation (Sousa et al. 2001b). In FAP there is also evidence of oxidative stress and inflammation (Sousa et al. 2001a; b; Macedo et al. 2007); published data show that α B-crystallin modulates inflammatory (TNF α) and oxidative stress pathways (Mehlen et al. 1996). It is plausible that α B-crystallin, as a defense mechanism, enhances survival or delay cell death by all these different pathways.

Acknowledgements

We thank Tânia Ribeiro, Rossana Correia, Paul Moreira and Paula Sampaio from IBMC for animal maintenance, tissue processing, TTR production, and confocal microscopy respectively. The authors also thank João Sousa now at Minho University (Portugal) for support in aggregate extraction studies. This study was supported by Fundação para a Ciência e Tecnologia (FCT) through fellowships SFRH/BD/35980/2007 (JM) and SFRH/BPD/20738/2004 (SDS) and grant PIC/IC/82824/2007.

References

Andrade C. (1952) A peculiar form of peripheral neuropathy. Familial atypical generalized amyloidosis with special involvement of the peripheral nerves. *Brain* 75, 408–427.

- Björkdahl C., Sjögren M.J., Zhou X. et al. (2008) Small heat shock proteins Hsp27 or α B-crystallin and the protein components of neurofibrillary tangles: tau and neurofilaments. *J. Neurosci. Res.* 86, 1343–1352.
- Cardoso I., Goldsberry C.S., Müller S.A. et al. (2002) Transthyretin fibrillogenesis entails the assembly of monomers: a molecular model for in vitro assembled transthyretin amyloid-like fibrils. *J. Mol. Biol.* 317, 683–695.
- Costa P.P., Figueira A.S., Bravo F.R. (1978) Amyloid fibril protein related to prealbumin in familial amyloidotic polyneuropathy. *Proc. Natl. Acad. Sci. U S A* 75, 4499–4503.
- Ecroyd H., Carver J. (2009) Crystallin proteins and amyloid fibrils. *Cell. Mol. Life Sci.* 66, 62–81.
- Ecroyd H., Meehan S., Horwitz J. et al. (2007) Mimicking phosphorylation of α B-crystallin affects its chaperone activity. *Biochem. J.* 401, 129–141.
- Fonte V., Kapulkin V., Taft A., Fluet A., Friedman D., Link C.D. (2002) Interaction of intracellular beta amyloid peptide with chaperone proteins. *Proc. Natl. Acad. Sci. U S A* 99, 9439–9444.
- Furuya H., Saraiva M.J., Gawinowicz M.A. et al. (1991) Production of recombinant human transthyretin with biological activities toward the understanding of the molecular basis of familial amyloidotic polyneuropathy (FAP). *Biochemistry* 30, 2415–2421.
- Ghosh J.G., Houck S.A., Clark J.I. (2008) Interactive sequences in the molecular chaperone, human α B-crystallin modulate the fibrillation of amyloidogenic proteins. *Int. J. Biochem. Cell Biol.* 40, 954–967.
- Henzel W.J., Billeci T.M., Stults J.T., Wond S.C., Grimley C., Watanabe C. (1993) Identifying proteins from two-dimensional gels by molecular mass searching of peptide fragments in protein sequence databases. *Proc. Natl. Acad. Sci. U S A* 90, 5011–5015.
- Jakob U., Gaestel M., Engel K., Buchner J. (1993) Small heat shock proteins are molecular chaperones. *J. Biol. Chem.* 268, 1517–1520.
- Kamradt M.C., Lu M., Werner M.E. et al. (2005) The small heat shock protein α B-crystallin is a novel inhibitor of TRAIL-induced apoptosis that suppresses the activation of caspase-3. *J. Biol. Chem.* 280, 11059–11066.
- Kaplan B., German G., Ravid M., Pras M. (1994) Determination of amyloid type by ELISA using milligram amounts of tissue. *Clin. Chim. Acta* 229, 171–179.
- Klemenz R., Fröhli E., Steiger R.H., Schäfer R., Aoyama A. (1991) α B-crystallin is a small heat shock protein. *PNAS* 88, 3652–3656.
- Kohno K., Palha J.A., Miyakawa K. et al. (1997) Analysis of amyloid deposition in a transgenic mouse model of homozygous familial amyloidotic polyneuropathy. *Am. J. Pathol.* 150, 1497–1508.
- Liu S., Li J., Tao Y., Xiao X. (2007) Small heat shock protein AlphaB-crystallin binds to p53 to sequester its translocation to mitochondria during hydrogen peroxide-induced apoptosis. *Biochem. Biophys. Res. Commun.* 354, 109–114.
- Macedo B., Batista A.R., do Amaral J.B., Saraiva M.J. (2007) Biomarkers in the assessment of therapies for Familial Amyloidotic Polyneuropathy. *Mol. Med.* 13, 584–591.
- Magrané J., Smith R.C., Walsh K., Querfurth H.W. (2004) Heat shock protein 70 participates in the neuroprotective response to intracellularly expressed beta-amyloid in neurons. *J. Neurosci.* 24, 1700–1706.
- Mao Y.W., Liu J.P., Xiang H., Li D.W. (2004) Human AlphaA- and AlphaB-crystallins bind to Bax and Bcl-X(S) to sequester their translocation during staurosporine-induced apoptosis. *Cell Death Differ.* 11, 512–526.

- Mehlen P., Kretz-Remy C., Prévaille X., Arrigo A.P. (1996) Human hsp27, Drosophila hsp27 and human α B-crystallin expression-mediated increase in glutathione is essential for the protective activity of these proteins against TNF α -induced cell death. *EMBO J.* **15**, 2695–2706.
- Outeiro T.F., Klucken J., Strathearn K.E. *et al.* (2006) Small heat shock proteins protect against alpha-synuclein-induced toxicity and aggregation. *Biochem. Biophys. Res. Commun.* **351**, 631–638.
- Pokrzywa M., Dacklin I., Hultmark D., Lundgren E. (2007) Misfolded transthyretin causes behavioral changes in a Drosophila model for transthyretin-associated amyloidosis. *Eur. J. Neurosci.* **26**, 913–924.
- Raman B., Ban T., Sakai M. *et al.* (2005) AlphaB-crystallin, a small heat-shock protein, prevents the amyloid fibril growth of an amyloid beta-peptide and beta2-microglobulin. *Biochem. J.* **392**, 573–581.
- Renkawek K., Voorter C.E., Bosman G.J., van Workum F.P., de Jong WW. (1994) Expression of α B-crystallin in Alzheimer's disease. *Acta Neuropathol.* **87**, 155–160.
- Santos S.D., Cardoso I., Magalhães J., Saraiva M.J. (2007) Impairment of the ubiquitin-proteasome system associated with extracellular transthyretin aggregates in familial amyloidotic polyneuropathy. *J. Pathol.* **213**, 200–209.
- Santos S.D., Magalhães J., Saraiva M.J. (2008) Activation of the heat shock response in familial amyloidotic polyneuropathy. *J. Neuropathol. Exp. Neurol.* **67**, 449–455.
- Santos S.D., Fernandes R., Saraiva M.J. (2010) The heat shock response modulates transthyretin deposition in the peripheral and autonomic nervous systems. *Neurobiol. Aging* **31**, 280–309.
- Saraiva M.J., Birken S., Costa P.P., Goodman D.S. (1984) Family studies of the genetic abnormality in transthyretin (prealbumin) in Portuguese patients with familial amyloidotic polyneuropathy. *Ann. N Y Acad. Sci.* **435**, 86–100.
- Shen H.Y., He J.C., Wang Y., Huang Q.Y., Chen J.F. (2005) Geldanamycin induces heat shock protein 70 and protects against MPTP-induced dopaminergic neurotoxicity in mice. *J. Biol. Chem.* **280**, 39962–39969.
- Sittler A., Lurz R., Lueder G. *et al.* (2001) Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease. *Hum. Mol. Genet.* **10**, 1307–1315.
- Sousa M.M., Cardoso I., Fernandes R., Guimarães A., Saraiva M.J. (2001a) Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. *Am. J. Pathol.* **159**, 1993–2000.
- Sousa M.M., Du Yan S., Fernandes R., Guimaraes A., Stern D., Saraiva M.J. (2001b) Familial amyloid polyneuropathy: receptor for advanced glycation end products-dependent triggering of neuronal inflammatory and apoptotic pathways. *J. Neurosci.* **21**, 7576–7586.
- Sousa M.M., Fernandes R., Palha J.A., Taboada A., Vieira P., Saraiva M.J. (2002) Evidence for early cytotoxic aggregates in transgenic mice for human transthyretin Leu55Pro. *Am. J. Pathol.* **161**, 1935–1948.
- Teixeira P.F., Cerca F., Santos S.D., Saraiva M.J. (2006) Endoplasmic reticulum stress associated with extracellular aggregates. Evidence from transthyretin deposition in familial amyloid polyneuropathy. *J. Biol. Chem.* **281**, 21998–22003.
- Wilhelmus M.M., Otte-Höller I., Wesseling P., de Waal R.M., Boelens W.C., Verbeek M.M. (2006) Specific association of small heat shock proteins with the pathological hallmarks of Alzheimer's disease brains. *Neuropathol. Appl. Neurobiol.* **32**, 119–130.